A phase II evaluation of sunitinib (SU11248) in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG) study

2015 ◽  
Vol 138 ◽  
pp. 3 ◽  
Author(s):  
J. Chan ◽  
W.E. Brady ◽  
J. Brown ◽  
M.S. Shahin ◽  
P.G. Rose ◽  
...  
Keyword(s):  
Ovarian Carcinoma ◽  
Phase Ii ◽  
Clear Cell ◽  
Gynecologic Oncology ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Clear Cell Ovarian Carcinoma

Intraperitoneal Interferon-α in Residual Ovarian Carcinoma: A Phase II Gynecologic Oncology Group Study

1999 ◽  
Vol 75 (1) ◽  
pp. 10-14 ◽  
Author(s):  
Jonathan S. Berek ◽  
Maurie Markman ◽  
Bette Stonebraker ◽  
Samuel S. Lentz ◽  
Mark D. Adelson ◽  
...  
Keyword(s):  
Ovarian Carcinoma ◽  
Phase Ii ◽  
Gynecologic Oncology ◽  
Interferon Α ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Oncology Group Study

Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.

1991 ◽  
Vol 9 (7) ◽  
pp. 1138-1150 ◽  
Author(s):  
G A Omura ◽  
M F Brady ◽  
H D Homesley ◽  
E Yordan ◽  
F J Major ◽  
...  
Keyword(s):  
Ovarian Carcinoma ◽  
Clear Cell ◽  
Gynecologic Oncology ◽  
Gynecologic Oncology Group ◽  
Oncology Group ◽  
Advanced Ovarian Carcinoma ◽  
Second Look ◽  
Long Term Follow Up

Long-term follow-up was obtained on 726 women with advanced ovarian carcinoma (suboptimal stage III and stage IV) who had received primary chemotherapy on two Gynecologic Oncology Group (GOG) protocols between 1976 and 1982. The first study compared melphalan alone versus melphalan plus hexamethylmelamine versus cyclophosphamide plus doxorubicin (CA). The second study evaluated the same CA regimen with or without cisplatin. Eligibility for the two studies was the same. At last contact, 76 patients were alive. In a multivariate analysis, cell type other than clear cell or mucinous, cisplatin-based treatment, good performance status, younger age, lower stage, clinically nonmeasurable disease, smaller residual tumor volume, and absence of ascites were favorable characteristics for overall survival (P less than .05). Second-look laparotomy was negative significantly more often among those with endometrioid tumors; there were no negative second-look laparotomies among those with mucinous or clear cell tumors. There were 30 patients with suboptimal stage III disease who had a negative second-look laparotomy; 18 (60%) have experienced recurrence, and 13 (43%) have died. Although cisplatin treatment was beneficial, new treatments are clearly needed.

Sign in / Sign up

Export Citation Format

Share Document